Although PARP1 inhibitors are used to treat malignancies (such as cervical and ovarian cancer) that often possess BRCA1/2 mutations and an impaired homologous-recombination (HR) mechanism [49,50], the use of PAPR1 inhibitors in the CRC treatment has not yet been well established and is the subject of current investigations. This evidence concerns the gene PARP1 and colorectal carcinoma.